600671.SS SHH
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
1W: -8.8%
1M: -4.7%
3M: +21.8%
YTD: +8.0%
1Y: +46.1%
3Y: +165.4%
5Y: +164.8%
¥21.79 ($3.25)
+0.17 (+0.79%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$217M
+78.4% ▲
5Y CAGR: -6.1%
Gross Profit
$103M
+339.7% ▲
5Y CAGR: -6.9%
Operating Income
$25M
+166.8% ▲
Net Income
$15M
+139.8% ▲
5Y CAGR: -21.4%
EPS (Diluted)
$0.13
+141.9% ▲
5Y CAGR: -20.9%
EBITDA
$57M
+502.3% ▲
5Y CAGR: -5.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $207M | $147M | $109M | $122M | $217M |
| YoY Growth | -30.4% | -28.8% | -25.9% | +11.8% | +78.4% |
| Cost of Revenue | $126M | $101M | $84M | $98M | $114M |
| Gross Profit | $80M | $46M | $25M | $23M | $103M |
| Gross Margin | 38.8% | 31.2% | 22.9% | 19.2% | 47.4% |
| R&D Expenses | $643K | $1M | $2M | $482K | $1M |
| SG&A Expenses | $64M | $37M | $18M | $16M | $21M |
| Operating Expenses | $85M | $64M | $53M | $61M | $78M |
| Operating Income | $990K | -$18M | -$28M | -$38M | $25M |
| Operating Margin | 0.5% | -12.4% | -26.1% | -30.9% | 11.6% |
| Interest Expense | $7M | $8M | $7M | $7M | $6M |
| Income Before Tax | -$51M | -$34M | -$72M | -$36M | $29M |
| Tax Expense | $935K | -$954K | $842K | $3M | $7M |
| Net Income | -$52M | -$33M | -$73M | -$38M | $15M |
| Net Margin | -24.9% | -22.3% | -67.2% | -31.4% | 7.0% |
| EPS (Diluted) | $-0.42 | $-0.27 | $-0.60 | $-0.31 | $0.13 |
| EBITDA | -$33M | -$14M | -$44M | -$14M | $57M |
| Shares Outstanding | 122M | 122M | 122M | 122M | 122M |